Hervé Hoppenot, Incyte CEO (Jeff Rumans)
June 24, 2021 03:36 PM EDTUpdated June 25, 07:53 AM
FDA+

ODAC echoes FDA con­cern over In­cyte PD-1, as Paz­dur sig­nals broad­er shift for ac­cel­er­at­ed ap­proval

Max Gelman

Senior Editor

Af­ter the FDA lam­bast­ed their PD-1 ahead of an ad­comm ear­li­er this week, In­cyte ran in­to new trou­ble Thurs­day as ODAC pan­elists vot­ed against an …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

Bris­tol My­ers re­veals more job cuts in New Jer­sey

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Mer­ck halts Phase 3 tri­al with PAH drug Win­re­vair fol­low­ing pos­i­tive in­ter­im da­ta 

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Cas­sa­va shares plunge as con­tro­ver­sial Alzheimer’s drug fails Phase 3 tri­al

A service from the Financial Times